Intellectual disability, autism spectrum disorder, and epilepsy are prime examples of neurodevelopmental disorders that collectively affect a significant percentage of the world population. Recent technological breakthroughs allowed the elucidation of the genetic causes of many of these disorders. As neurodevelopmental disorders are genetically heterogeneous, the development of rational therapy is extremely challenging. Fortunately, many causative genes are interconnected and cluster in specific cellular pathways. Targeting a common node in such a network would allow us to interfere with a series of related neurodevelopmental disorders at once. Here, we argue that the GABAergic system is disturbed in many neurodevelopmental disorders, including fragile X syndrome, Rett syndrome, and Dravet syndrome, and is a key candidate target for therapeutic intervention. Many drugs that modulate the GABAergic system have already been tested in animal models with encouraging outcomes and are readily available for clinical trials.
Neurodevelopmental disorders, including autism spectrum disorder (ASD), intellectual disability (ID), and epilepsy are the consequences of a disturbance of CNS development that presents clinically as impairments in personal, social, academic, or occupational functioning. Technological breakthroughs-in particular, the development of high-capacity sequencing machines-facilitated the discovery of an increasing number of causative genes over the last few years (Coe et al., 2014; De Rubeis et al., 2014; Gilissen et al., 2014; Iossifov et al., 2014) . The search has been particularly successful in the identification of genes that underlie syndromic forms of neurodevelopmental disorders, such as in patients with a combination of ASD, ID, and epilepsy. For instance, the SCN2A gene was originally considered an epilepsy gene, but in more recent studies, it was also found mutated in patients with ASD and with ID . All gene identification studies demonstrate a substantial heterogeneity in the genetic causes, and it has been estimated that 1,500-2,000 genes are responsible for ID alone (van Bokhoven, 2011) . This means that, with very few exceptions, only a limited number of patients with a causative mutation in the same gene have been identified. This genetic heterogeneity frustrates attempts to develop rational therapy for individual disorders and initiatives aimed at treatment of neurodevelopmental disorders are lagging (Green and Guyer, 2011) .
Emerging evidence suggests that many of the genes responsible for individual neurodevelopmental disorders cluster in a relatively limited number of modules that operate in the same molecular processes (Epi4K Consortium and Epilepsy Phenome/Genome Project, 2013; Gilman et al., 2011; O'Roak et al., 2012; Voineagu et al., 2011) . The encoded proteins converge on a relatively limited number of protein-protein interaction (PPI) networks, including those that are involved in synaptic functioning and in chromatin remodeling (De Rubeis et al., 2014; Krumm et al., 2014) . This network concept is relevant with respect to the prospects for therapy, as interference with a pathway disturbed in a group of disorders might bring therapy for rare neurodevelopmental disorders one step closer to reality.
In this Perspective, we argue that the GABAergic system is a key pathway that is commonly disturbed in many neurodevelopmental disorders. We recently provided an overview how, in fragile X syndrome, animal experiments led to the initiation of clinical trials . Here, we illustrate that, in many more neurodevelopmental disorders, this key inhibitory pathway is disturbed. We aim to encourage initiatives to set up clinical trials with the appropriate drugs that are on or close to the market, as we believe that targeting the GABAergic abnormalities may be an unique opportunity for treatment for this type of disorder. Proper inhibitory GABAergic signaling is essential for normal neural circuit function (reviewed by Hu et al., 2014; Ramamoorthi and Lin, 2011; Rudolph and Mö hler, 2014) . Although only present in a minority of neurons, diverse populations of GABAergic interneurons regulate the much more uniform majority of excitatory neurons. If the inhibition is disturbed, excessive excitation results in a disturbance in the excitatory/ inhibitory balance (E/I balance) and, consequently, in a dysfunction of cognitive processes. p subunit, and the b subunit can be replaced by a q subunit. Distinct receptor subtypes have a specific regional, cellular, and subcellular expression pattern (Olsen and Sieghart, 2008) . For instance, GABA A receptors that contain an a 1-3 , b n , and g 2 subunit are mainly synaptic, whereas a 4-6 and d-containing receptors are mainly peri-or extrasynaptically located (Belelli et al., 2009; Farrant and Nusser, 2005; Glykys and Mody, 2007) . Synaptic receptors mediate fast phasic inhibition, whereas extrasynaptic receptors produce persistent tonic inhibition. In contrast to the inhibitory action in the adult brain, GABA A receptors are depolarizing and often excitatory during early development ( Figure 1B ) (Ben-Ari, 2002) . This is a consequence of developmental changes in chloride homeostasis, tightly regulated by the Na + -K + -2Cl À co-transporter 1 (NKCC1/SLC12A2) and the K + -Cl À co-transporter 2 (KCC2/SLC12A5). The chloride importer NKCC1 maintains high intracellular chloride concentrations in immature neurons. Consequently, activation of GABA A receptors in these neurons results in chloride efflux and membrane depolarization. During development, the expression of the chloride exporter KCC2 is upregulated, with a concomitant downregulation of NKCC1 ( Figure 1C ). This shift in balance between chloride importers and exporters results in a progressive decrease in intracellular chloride concentration, which induces the excitation-inhibition switch in GABA A receptor-mediated signaling.
Known Consequences of Genetic Variation in the GABAergic System
There is clear evidence for the involvement of GABA A receptors in neurodevelopmental disorders (Table 1) . Mutations in the a 1 subunit have been identified in patients suffering from early infantile epileptic encephalopathy, juvenile myoclonic epilepsy, and other types of seizure disorders (Carvill et al., 2014; Cossette et al., 2002; Maljevic et al., 2006; Epi4K Consortium and Epilepsy Phenome/Genome Project, 2013) . Mutations in the b 3 subunit have been identified in children with absence epilepsy (Epi4K Consortium and Epilepsy Phenome/Genome Project, 2013; Tanaka et al., 2008) . Other subunits in which mutations have been identified in patients with various forms of epilepsy disorders include the g 2 and d subunits (Baulac et al., 2001; Dibbens et al., 2004) . In the Prader-Willi/Angelman syndromes, a pair of neurodevelopmental disorders caused by the paternal and maternal deletions, respectively, of a chromosomal region on 15q11-13, three genes encoding subunits of the GABA A receptor are deleted. A reciprocal duplication of the same chromosomal region results in autism. A gene dosage imbalance of (A) Gamma aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the adult mammalian brain (Olsen and Sieghart, 2008) . GABA is synthesized from glutamate by the enzyme glutamic acid decarboxylase (GAD) (Erlander et al., 1991) . Two isoforms of this enzyme exist: GAD67 encoded by GAD1 and GAD65 encoded by GAD2. GABA is packed into presynaptic vesicles by vesicular GABA transporters (VGAT/SLC32A1) (Gasnier, 2004) . Following an action potential, GABA is released into the synaptic cleft by fusion of the vesicles to the cell membrane. Once released, GABA can interact with two types of receptors: ionotropic GABA A receptors (Olsen and Sieghart, 2008) or metabotropic GABA B receptors (Bowery et al., 2002; Gassmann and Bettler, 2012) . The action of GABA is terminated by reuptake into the presynaptic neuron or a glial cell by GABA transporters (GAT1/SLC6A1, GAT3/ SLC6A11, BGT-1/SLC6A12, and GAT2/SLC6A13) or by diffusion from the synaptic cleft (Madsen et al., 2010) . GABA is degraded by the enzyme GABAtransaminase (GABA-T/ABAT) and converted to glutamate and succinic semialdehyde (SSA). The latter is used by the enzyme SSADH/ALDH5A1 to generate succinate for the Krebs cycle (Rowley et al., 2012) . (B) During early development, GABA A R-mediated signaling is depolarizing due to high expression of NKCC1 and high intracellular chloride concentration. (C) Due to an upregulation of KCC2, the intracellular chloride concentration decreases and GABA A R-mediated signaling becomes hyperpolarizing during development. Putative therapeutic compounds are indicated in red.
GABRA5, GABRB3, and GABRG3 contributes to the developmental delay, autism, and other clinical features observed in these contiguous gene syndromes in addition to the imprinting defects. Sequence variants of unknown significance in GABRB2
could possibly contribute to intellectual disability and epilepsy (Srivastava et al., 2014) . An association with autism has been reported for SNPs in GABRA4 and an association with generalized epilepsy has been suggested for GABRA6 (Ma et al., Prasad et al., 2014) . Associations with alcohol dependence have been reported for SNPs in GABRA2 and GABRA6 (Li et al., 2014) . Both mutations in the GABA synthesis and transporter genes have also been associated with disease. Recessive mutations in GAD1 cause cerebral palsy, a posture or movement disorder caused by a brain abnormality first evident at the stage of rapid brain development (Lynex et al., 2004) . GABA transaminase deficiency, due to mutations in both copies of the ABAT gene, results in severe psychomotor retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, high-pitched cry, and electroencephalogram (EEG) abnormalities (Medina-Kauwe et al., 1999 ). An excess of GABA underlies succinic semialdehyde dehydrogenase (SSADH) deficiency, a neurologic disorder characterized by hypotonia, intellectual disability, ataxia, seizures, hyperkinetic behavior, aggression, and sleep disturbances (Reis et al., 2012) . It is caused by recessive mutations in ALDH5A1, an enzyme in the GABA degradation pathway, that result in an elevation of gamma-hydroxybutyric acid (GHB) and GABA in the brain. Mutations in the Na-K-Cl co-transporter NKCC1/SLC12A2 cause Bartter syndrome, a primarily nephrological syndrome with neurological involvement (Baird et al., 2006) . Although only observed in a single pedigree, the R952H variant in the K-Cl co-transporter KCC2/SLC12A5 is a bona fide candidate for febrile seizures (Puskarjov et al., 2014) . A microdeletion encompassing the GABA transporters SLC6A1 and SLC6A11 on chromosome 3p25.3 results in intellectual disability, epilepsy, and stereotypic behavior (Dikow et al., 2014) .
The GABAergic System Can Be Influenced by Pharmacological Compounds GABA A receptors can be targeted by a wide variety of pharmacological compounds (Carver and Reddy, 2013; D'Hulst et al., 2009; Rudolph and Knoflach, 2011) . The majority of these compounds binds to allosteric sites of the receptor. Well-known allosteric modulators include the benzodiazepines, which have anticonvulsant and anxiolytic effects. These drugs had their reputation damaged because of adverse side effects that include sedation, physical dependence, and abuse liability. In later years, the functional properties of benzodiazepines were allocated to distinct GABA A receptor subtypes, and it was determined that the a 1 subunits mediate the sedative effects, while a 2/3 subunits mediate the anxiolytic effects (McKernan et al., 2000; Rudolph et al., 1999) . L-838,417 and TPA-023 are examples of candidate drugs that target the a 2/3 subtypes selectively (Rudolph and Knoflach, 2011; Rudolph and Mö hler, 2014) . A very different class of allosteric modulators is the neurosteroids or neuroactive steroids, which bind the neurosteroid binding site of the receptor (Carter et al., 1997; Carver and Reddy, 2013; Nohria and Giller, 2007) . Neurosteroids interact with both synaptic and extrasynaptic GABA A receptors, with a preference for d-containing, extrasynaptic GABA A receptor subtypes. Synthetic derivatives of the endogenous neurosteroid allopregnalone, such as alphaxalone and ganaxolone (3a-hydroxy3b-methyl-5a-pregnan-20-one), are available (Nohria and Giller, 2007) . Additional candidate drugs include gaboxadol (also known as THIP), a GABA-mimetic and superagonist at extrasynaptic d-containing GABA A receptors (Wafford and Ebert, 2006) . RO4938581 and alpha5IA are inverse agonists of the a 5 subunit, a subtype involved in cognition (Atack, 2008; Ballard et al., 2009; Dawson et al., 2006) .
Apart from modulating the activity of the GABAergic system by interfering directly with the receptor, pharmacological compounds can also interfere with synaptic GABA concentrations ( Figure 1A ). Tiagabine is a GABA reuptake inhibitor that specifically blocks the GABA transporter GAT1 (Madsen et al., 2010) . Vigabatrin is an irreversible inhibitory of GABA-T, thus blocking GABA catabolism (Rowley et al., 2012) . Immature GABA A receptor signaling can be targeted with bumetanide, an inhibitor of NKCC1, which decreases the intracellular chloride concentration.
As the subunits of the GABA A receptor are non-uniformly distributed though the brain, the choice of drugs has an influence on the brain region targeted. For instance, the a 5 subunit is predominantly present in the hippocampus, and the subtype-selective compounds RO4938581 and alpha5IA will, therefore, mostly act in that brain region, whereas tiagabine, for instance, will have a much more evenly distributed effect. Depending on the characteristics of the abnormalities of the GABAergic system abnormalities, different drugs can be applied.
What We Know about GABAergic Deficits in Neurodevelopmental Disorders
Fragile X Syndrome The primary characteristics of fragile X syndrome (Online Mendelian Inheritance in Man [OMIM] ID number 300624), a frequent form of inherited ID, include cognitive and behavioral problems, facial dysmorphism, and macroorchidism (Hagerman, 2002) . Epileptic seizures are common (Musumeci et al., 1999) . Fragile X syndrome is associated with ASD in approximately half of the cases (Harris et al., 2008; Kaufmann et al., 2004; Lewis et al., 2006) . Specific autistic features include gaze avoidance, hand flapping, repetitive behaviors, and speech perseveration. The disorder is caused by a dynamic, inactivating mutation in the FMR1 gene (Verkerk et al., 1991) . The encoded protein, FMRP, is thought to interact with hundreds of neuronal mRNAs (Ascano et al., 2012; Darnell et al., 2011; Suhl et al., 2014) , and its absence affects numerous molecular pathways in the cell (Darnell and Klann, 2013) . Experimental Evidence from Animal Models for the Involvement of the GABAergic System An increasing number of studies in Fmr1 knockout mice, a validated mouse model for the human disorder, support the hypothesis of an impaired inhibitory, GABAergic system in fragile X syndrome (reviewed by Cea-Del Rio and Huntsman, 2014; Paluszkiewicz et al., 2011) . Age-and brain-region-dependent differential expression has been reported for several GABA A receptor subunits and multiple other components of the GABAergic system, including enzymes involved in GABA synthesis (Gad1 and Gad2), GABA transporters (Slc6a1 and Slc6a11), an enzyme involved in GABA degradation (Aldh5a1), and a targeting and clustering protein (Gphn). Moreover, altered phasic and/or tonic GABA A receptor-mediated signaling has been observed in the subiculum, basolateral amygdala, somatosensory cortex, and striatum. Decreased GABA concentrations have been reported in several brain regions. Interneuron subtype-specific neuroanatomical deficits have been reported in the somatosensory cortex. In addition to an overall downregulation of the GABAergic system that is brain region and age dependent, a delayed excitation-inhibition switch of GABA A receptors has been reported in the somatosensory cortex of Fmr1 knockout mice from postnatal day 10 to postnatal day 14 . The delayed GABA polarity switch in Fmr1 knockout mice was paralleled by a higher NKCC1 expression in that period of development. Apart from the delay in the permanent polarity switch in the second postnatal week, the transient excitation-inhibition switch triggered by the maternal hormone oxytocin, which causes an abrupt decrease in intracellular chloride concentrations during delivery, is absent from hippocampal CA3 pyramidal neurons of Fmr1 knockout mice (Tyzio et al., 2014) . Preclinical Studies Highlight the Therapeutic Potential of the GABA A Receptor The GABA A receptor as a therapeutic target for fragile X syndrome was first postulated in 2007 (D' Hulst and Kooy, 2007) . A high-throughput screening of a library of 2,000 compounds in a fragile X fly model for their ability to rescue the glutamateinduced lethality in dfmr1 mutants demonstrated that three of the nine lead compounds were modulators of the GABAergic system (Chang et al., 2008) . These include GABA itself, nipecotic acid, a GABA reuptake inhibitor, and creatinine, a GABA A receptor activator. Each of these compounds was able to correct specific phenotypes of dfmr1-deficient Drosophila, such as b-lobe crossing in the mushroom body and diminished courtship behavior. This paper provided the first experimental evidence that increasing GABAergic signaling-either directly through stimulation of GABA A receptors (GABA and creatinine) or indirectly by increasing synaptic GABA concentrations (nipecotic acid)-is able to restore the abnormalities observed in a fly model. GABA itself is not suitable for treatment in mice, as it does not cross the blood-brain barrier. Subsequent studies with the GABA-mimetic gaboxadol in Fmr1 knockout mice demonstrated a correction of hyperactivity as measured in the open field and modulation of altered sensorimotor gating, measured as increased prepulse inhibition after acute treatment (Olmos-Serrano et al., 2011) .
Acute treatment of Fmr1 knockout mice with ganaxolone completely prevented audiogenic seizures (Heulens et al., 2012) and corrected repetitive/perseverative behavior in a marble-burying assay in a dose-dependent manner and partially corrected prepulse inhibition abnormalities . Moreover, acute maternal pre-treatment with the NKCC1 antagonist bumetanide was able to restore the excitation-inhibition switch in neonatal Fmr1 knockout mice and corrected electrophysiological and behavioral phenotypes (Tyzio et al., 2014) .
Rett Syndrome
Patients with Rett syndrome (OMIM ID number 312750), an ASD caused by loss-of-function mutations of the methyl-CpG-binding protein 2 (MECP2) gene on Xq28, may develop normally until 6-18 months of age, after which a regression phase occurs, accompanied by a loss of acquired skills (reviewed by Chahrour and Zoghbi, 2007; Neul et al., 2010) . Associated autistic-like features include social withdrawal, lack of eye contact, and indifference to the surrounding environment, but the clinical spectrum of the disorder also involves intellectual disability, epileptic seizures, breathing abnormalities, and hypotonia. Following the identification of MECP2 as the causal gene (Amir et al., 1999) , a variety of mouse models was generated (reviewed by Calfa et al., 2011; Katz et al., 2012) , with the Mecp2 tm1.1Bird (deletion of a fragment containing exons 3 and 4) (Guy et al., 2001 ) and Mecp2 tm1.1Jae (exon 3 deletion) (Chen et al., 2001 ) models being most commonly used. These mouse models recapitulate many features of Rett syndrome, including cognitive and behavioral aberrations, motor impairments, breathing abnormalities, and premature lethality. Electrophysiological recordings in Mecp2 tm1.1Bird mice show decreased basal inhibitory rhythmic activity in the CA3 region of the hippocampus and decreased phasic inhibition in the ventrolateral medulla (Medrihan et al., 2008) and in the locus coeruleus (Jin et al., 2013) . MeCP2 deficiency in the thalamus leads to opposite changes in excitatory and inhibitory neurons, with reduced miniature inhibitory postsynaptic current (mIPSC) frequency in excitatory ventrobasal complex neurons and increased mIPSC frequency in inhibitory reticular thalamic nucleus neurons (Zhang et al., 2010) . Moreover, several components of the GABAergic system were differentially expressed due to MeCP2 deficiency. A significant reduction was observed in a 2 and a 4 subunit mRNA expression in the ventrolateral medulla, without changes in the other a, b, and g subunits (Medrihan et al., 2008) . The mRNA and protein expression levels of vesicular inhibitory amino acid transporter/GABA vesicular transporter (VIAAT/VGAT) (Slc32a1) were also reduced in this brain region. In the thalamus, VIAAT/VGAT immunostaining was decreased in excitatory ventrobasal complex neurons and increased in inhibitory reticular thalamic nucleus neurons in the thalamus (Zhang et al., 2010) . El-Khoury et al. (2014) reported brain-region-and age-dependent alterations in the GABAergic system of MeCP2-deficient mice, including decreased GABA levels in the hippocampus, substantia nigra pars reticulata, and cerebellum; altered mRNA expression; and protein expression of GABAergic markers in the caudate putamen, ventral midbrain, and hippocampus. Recently, Tomassy et al. (2014) reported subtype-specific morphological alterations in neocortical interneurons. Loss of Mecp2 from GABAergic neurons in Viaat-Mecp2 À/y mice recapitulates many features of Rett syndrome, including premature lethality, motor dysfunction, breathing abnormalities, impaired spatial memory, stereotypic behavior, altered social interactions, and sensorimotor gating deficits (Chao et al., 2010) . Mice with a forebrain-specific and GABAergic-neuron-specific deletion of Mecp2 (Dlx5/6-Mecp2 À/y ) recapitulated a subset of Rett characteristics such as motor dysfunction, stereotypic behavior, altered social interactions, and sensorimotor gating deficits. These murine findings are supported by abnormalities in the GABAergic system detected in Rett syndrome patients. While GABA concentrations in the cerebrospinal fluid of girls with Rett syndrome appeared unaltered (Perry et al., 1988) , GABA A receptor binding was significantly increased in the caudate at a young age, as measured by 3 H-muscimol receptor autoradiography on postmortem basal ganglia slices (Blue et al., 1999) . On the other hand, in vivo 123 I-iomazenil single-photon emission computed tomography (SPECT) scans revealed decreased GABA A receptor binding in the frontotemporal cortex of adult female Rett syndrome patients (Yamashita et al., 1998) .
More recently, analysis of chloride co-transporters in the cerebrospinal fluid of young Rett syndrome patients showed decreased KCC2 protein expression and decreased KCC2/ NKCC1 ratio, reminiscent of immature GABA A receptor function (Duarte et al., 2013) (Figure 1) .
Preclinical studies in Rett mouse models revealed improvements in several domains after pharmacological correction of the GABAergic system deficits. The lifespan of Mecp2 tm1.1Bird male mice was significantly extended following chronic inhibition of GABA reuptake with tiagabine (El-Khoury et al., 2014) .
Respiratory problems in adult Mecp2
tm1.1Bird mice were significantly reduced by enhancing GABA A receptor-mediated signaling, either by blocking GABA reuptake or by positive allosteric modulation of the GABA A receptor itself (Abdala et al., 2010 (Dravet, 2011) . Common comorbid features include intellectual disability; behavioral problems such as hyperactivity; and autistic features, in combination with motor problems, including poor fine motor abilities, uncoordinated movements, hypotonia, and ataxia (Dravet, 2011; Li et al., 2011) . The majority of patients have a de novo heterozygous loss-of-function mutation in the SCN1A gene, which encodes for the a1 subunit of the voltagegated sodium channel Na V 1.1 (Claes et al., 2001 (Claes et al., , 2009 Lossin, 2009) .
Heterozygous knockout Scn1a mice (Scn1a tm1Wac ) display seizures and other characteristics compatible with the symptoms observed in patients, including premature death. A second mouse model containing a heterozygous loss-of-function nonsense mutation in the Scn1a gene (R1407X in exon 21 of Scn1a, Scn1a tm1.1Kzy /Scn1a RX1407X ) exhibits similar characteristics (Ogiwara et al., 2007) . While Na V 1.1 channels are expressed in both excitatory and inhibitory neurons, electrophysiological recordings indicated that Scn1a haploinsufficiency (Scn1a tm1Wac ) specifically reduces Na + currents and impairs action potential firing in GABAergic neurons in the hippocampus and cerebellum (Kalume et al., 2007; Ogiwara et al., 2007; Yu et al., 2006) . The resulting excitation-inhibition imbalance and hyperexcitability potentially relates to the epileptic phenotype in the hippocampus (Yu et al., 2006) and the ataxic phenotype in the cerebellum (Kalume et al., 2007) . Spontaneous IPSC (sIPSC) frequency was decreased, and spontaneous excitatory postsynaptic current (sEPSC) frequency was increased in the hippocampal CA1 region and the prefrontal cortex of Scn1a +/À slices compared to wild-type slices (Han et al., 2012) . Further support for the prominent involvement of the GABAergic deficits in Dravet syndrome was obtained from a conditional mouse model with Scn1a exclusively inactivated in the forebrain GABAergic neurons with the aid of a Dlx1/ 2-Cre promoter Han et al., 2012) . These Dlx1/2-Scn1a +/À mice phenocopy the global Scn1a +/À mutants, displaying premature death, spontaneous and temperature-dependent seizures , elevated locomotor activity in the open field, increased anxiety-like behavior in the open field and elevated plus maze, increased circling behavior, social interaction deficits in the open field social interaction test and three-chamber social preference test, and impaired contextual fear memory (Han et al., 2012) . Similarly, specific/selective Scn1a haploinsufficiency in parvalbuminpositive interneurons in the neocortex and hippocampus using the Ppp1r2-Cre mouse line resulted in spontaneous, temperature-dependent, and flurothyl-induced seizures (Dutton et al., 2013) . Acute treatment of Scn1a +/À mice (Scn1a tm1Wac ) with a low non-sedative and non-anxiolytic dose of the benzodiazepine clonazepam completely rescued impaired social behaviors in the open field social interaction test and the three chamber test, as well as the impairment in context-dependent fear memory (Han et al., 2012) . At the electrophysiological level, clonazepam increased sIPSC amplitude, which leads to a decrease in sEPSC frequency. Chronic treatment with a combination of the clonazepam and the GABA reuptake inhibitor tiagabine had a synergistic effect on seizure control (Oakley et al., 2013) .
GABAergic System Involvement in Additional Neurodevelopmental Disorders
Apart from fragile X, Rett, and Dravet syndromes mentioned earlier, evidence is accumulating that the GABAergic system is affected in other neurodevelopmental disorders. In neurofibromatosis type 1, caused by absence of a functional copy of the NF1 gene and associated with cognitive deficits, knockout mouse model studies suggested that increased GABA-mediated inhibitory neurotransmission is the neural mechanism underlying these deficits and that these deficits could be rescued by pharmalogical interference (Cui et al., 2008) . Tourette syndrome is a disorder of unknown genetic etiology that is associated with tics but also with attention deficit/hyperactivity disorder and obsessive-compulsive disorder. Abnormalities in brain GABA and, consequently, a loss of inhibition in these patients have been observed (Hallett, 2015) . The largest isoform of ANK3, a gene implicated in many neurodevelopmental and neuropsychiatric disorders, is involved in GABAergic synapse stability through interaction with a GABA-receptor-associated protein and through inhibition of receptor endocytosis (Tseng et al., 2015) . In Down syndrome, caused by a dosage imbalance of the genes on chromosome 21, dampening the excessive GABAergic inhibition with an a 5 -specific inverse agonist has been demonstrated to correct the cognitive disabilities in a mouse model (Rudolph and Mö hler, 2014) . However, autism, of unknown etiology, has been hypothesized to be the consequence of a disturbance in the E/I balance, and more recently, a downregulation of seven subunits of the GABA A receptor has been demonstrated postmortem in the frontal cortex of patients Rubenstein and Merzenich, 2003) . In the brains of schizophrenia patients, a decreased amount of NMDA (N-methyl-D-aspartic) receptor expression has been observed specifically in GABAergic neurons that is associated with a decrease in expression of the two GABA-synthesizing enzymes and several other components of the GABAergic system . While in each of these named disorders additional molecular pathways are affected-for instance, in fragile X syndrome, additional disturbed pathways include the endocannabinoid, glutamatergic, and muscarinic acetylcholine receptor systems, glycogen synthase kinase-3, extracellular signal-related kinase (ERK), mammalian target of rapamycin (mTOR), and p21-activated kinase signaling pathways and extracellular matrix metalloproteinase 9 (reviewed by Braat and Kooy, 2014) -the involvement of the GABAergic pathway is the only pathway involved in the pathophysiology of all named neurodevelopmental disorders. The mechanism underlying this disturbance is unknown and may differ between disorders. In fragile X syndrome, direct binding of the fragile X protein to specific subunits of the GABA A receptor has been demonstrated Miyashiro et al., 2003) , but it is unclear how and even if this binding causes the expression dysregulation.
Therapeutic Trials Based on GABAergic Treatment
Inspired by the preclinical test results in rodents, several trials in patients with drugs that interfere with the GABAergic system in patients have been set up. The efficacy of stiripentol in Dravet patients has been demonstrated in two placebo-controlled trials, as an add-on treatment in combination with valproate and clobazam (Chiron et al., 2000) . Stiripentol has multiple mechanisms of action, one of those being a direct allosteric modulator of GABA A receptors (Fisher, 2009; Quilichini et al., 2006) . It potentiates both phasic and tonic inhibition and binds at an allosteric site of the GABA A receptor, distinct from the benzodiazepine-and the neurosteroid-binding sites (Fisher, 2009; Grosenbaugh and Mott, 2013; Quilichini et al., 2006) . It acts at all GABA A receptor subtypes but has the highest activity at a 3 -and d-containing GABA A receptors. A two-center, phase II clinical trial with ganaxolone in fragile X patients is currently ongoing (https://www.clinicaltrials.gov [NCT] : ID number NCT01725152). Ganaxolone is a synthetic neurosteroid that is orally active, lacks hormonal side effects based on 3b-methyl substitution, and has limited adverse effects (Carter et al., 1997; Monaghan et al., 1997) . It has already been evaluated for its efficacy in various types of epilepsy in children and adults (Kerrigan et al., 2000; Laxer et al., 2000; Pieribone et al., 2007) . A randomized, double-blind, placebo-controlled crossover study aims to evaluate the efficacy of ganaxolone on aberrant behavior-in particular, with regard to anxiety and attention-in children with fragile X syndrome, with the Clinician's Global Impression-Improvement (CGI-I) as the primary outcome measure dysfunction (NCT: NCT01725152). In adults with Down syndrome, Hoffman-La Roche is running a clinical trial to test whether their compound RG1662 (related to RO4938581), an inverse agonist of the a 5 subunit, can reduce the severity of cognitive dysfunction (NCT: NCT01436955). The Erasmus Medical Center in Rotterdam is recruiting NF1 patients for inclusion in a trial to investigate the effect of lamotrigine on cognition (NCT: NCT02256124). This drug is an agonist of the hyperpolarization-activated, cyclic-nucleotide-gated channel 1 (HCN1) that is compromised predominantly in inhibitory interneurons of an animal model of the disorder. Lamotrigine has been demonstrated to correct the electrophysiological and the cognitive deficits in NF1 knockout mice (Omrani et al., 2015) . AZ7325/AZD7325 is an a 2 /a3-selective GABA A receptor-positive modulator that is currently evaluated in a phase II randomized, double-blind, placebo-controlled trial for its efficacy on social disability in young adults with ASD (NCT: NCT01966679). The primary outcome measure for this study is the effect of the compound on EEG patterns. In addition, side effects and measures of attention and learning will be monitored. The paradoxical effects of benzodiazepines on specific features, such as anxiety in some autism patients (Marrosu et al., 1987) , led to the hypothesis that GABA A receptors are excitatory rather than inhibitory in a subgroup of patients. These findings inspired a randomized controlled trial with bumetanide in children with autism or Asperger's syndrome (Lemonnier et al., 2012) . The diuretic bumetanide is clinically used to treat hypertension, broncho-pulmonary dysplasia, nephritic syndromes, or heart congestions. Significant improvements were observed in the Childhood Autism Rating Scale (CARS) and the Clinical Global Impressions (CGI), and Autism Diagnostic Observation Schedules (ADOS) in a subgroup of patients with a mild phenotype. A phase I trial to study the pharmacokinetics and safety of bumetanide in newborns with refractory seizures is currently ongoing (NCT: NCT00830531).
Thus far in this Perspective, we have focused on the GABA A receptor abnormalities. A single trial with arbaclofen (STX209), a GABA B receptor agonist, has been carried out in fragile X syndrome patients, inspired by a positive evaluation of the efficacy of this compound in animal studies (Henderson et al., 2012) . Metabotropic GABA B receptors are assembled as heterodimers, containing a GABA B1 and a GABA B2 subunit (Bowery et al., 2002; Gassmann and Bettler, 2012) . Through inhibition of neurotransmitter release at the presynaptic glutamatergic terminal, GABA B receptor agonists are thought to dampen excess excitatory mGluR signaling in Fmr1 knockout mice. It had been hypothesized that, by inhibiting this specific type of glutamatergic signaling, many of the symptoms of fragile X syndrome could be corrected (Bear et al., 2004) . Disappointingly, in a randomized double-blind, placebo-controlled crossover study in children and adults with fragile X syndrome, no significant improvements were detected in the primary endpoint, the Aberrant Behavior Checklist-Irritability (ABC-I) (Berry-Kravis et al., 2012) . However, post hoc analysis with the ABC-Social Avoidance scale specifically adapted for fragile X syndrome, revealed significant improvements in the entire study population. In addition, in a subgroup of patients with more severe social impairments, significant improvements were observed on the Vineland II-Socialization scale, on the ABC-Social Avoidance scale, and on all global measures. It remains difficult for us to comment on the meaning of the post hoc analysis. Because the Food and Drug Administration requires the effect of a new drug to predict a priori what it will do in the patient population and requires the conducted trials to determine whether the drug delivers the predicted results, this trial is officially registered as a failure. The reason for this attitude is the marginal significance that may be associated with the post hoc analysis and, consequently, the risk of reporting false-positive results. On the other hand, one can argue that, in the case of multisystem disorders such as fragile X syndrome, the precise clinical effects of the drug under study may be hard to predict and can only be identified once a pilot study has been completed. It is, therefore, a pity that the open label extension study with STX209 had to be terminated due to resource limitations from Seaside Therapeutics, the pharmaceutical company involved (NCT: NCT01555333).
Which Symptoms Can Be Targeted by Pharmalogical
Interference? So far, we have illustrated that mutations in components of the GABAergic system result in a range of neurodevelopmental disorders and that, at the same time, in many neurodevelopmental disorders, disturbances in the GABAergic system are apparent. Reported trials with GABAergic drugs in animal models reported correction of some behavioral abnormalities. Trials in patients have been initiated and some more are in the planning stages, but what can we expect from these trials in patients? While neurodevelopmental disorders, by definition, result from a disturbance during brain development and connections that have been miswired during developments are considered irreversible, recent studies in animal models suggest that it is possible to reverse certain deficits associated with these disorders in adults by genetic or pharmacological manipulations (reviewed in Castré n et al., 2012 ). An example is the fragile X mouse model. Conditional knockouts that allowed the Fmr1 gene to be switched on and off at selected times during development showed that most of the symptoms of the animal model could be reversed by reactivation of the gene in adulthood (David Nelson, personal communication) .
There is clear evidence for the involvement of GABA A receptors in epilepsy, anxiety, and insomnia (Table 1) , and we would expect improvements in these disorders, provided that drugs are able to compensate for the alterations in the GABAergic system in the patients. Cognition is predominantly associated with alterations in the level of a 5 subunits (Dawson et al., 2006) . Cognition enhancers in the form of a 5 enhancers have shown an effect in animal models but have not been tested in humans as yet (Rudolph and Mö hler, 2014) . As stated earlier, RG1662 is now in a clinical trial with, as a primary aim, the improvement of cognition in Down syndrome patients.
Pessimists will argue that chances of a successful completion of this specific trial or, in fact, any of the ongoing trials are slim: more than 80% of treatments that were shown effective in mouse studies failed in patients, despite the fact that the animal studies necessary to assess drug safety and therapeutic potential were successful (Perrin, 2014) . There has been much speculation on the origin of this discrepancy. A publication bias toward positive results and a lack of well-designed preclinical experiments are most frequently assumed to be responsible for the high failure rate. We would like to add to these arguments that, in some cases, clinical trials are inspired based on the results generated in a single laboratory. Given the variability in test results that may occur between laboratories even after rigorous standardization of the test battery (Crabbe et al., 1999) , an independent experimental confirmation in a second laboratory will, in our opinion, reduce the percentage of failed human trials. Another possible cause of the high failure rate is the lack of confirmation of the animal study results in the patient. Due to the scarcity of postmortem materials, this can only be realistically archived using imaging techniques. Using magnetic resonance spectroscopy (MRS) to measure GABA levels in patients with NF1, Violante et al. (2013) demonstrated a reduced quantity of this inhibitory neurotransmitter in the visual cortex. [
11 C]flumazenil positron emission tomography (PET) was used to demonstrate a reduced binding of GABA to its receptor in patients with SSADH deficiency (Pearl et al., 2009 Lucignani et al., 2004 ).
The Road Ahead
There is an immediate need for the development of therapy for neurodevelopmental disorders. Due to the genetic heterogeneity observed, targeted treatment aimed at interference with pathways commonly disturbed in multiple disorders might be the only realistic option. We have highlighted in this perspective (1) that the GABAergic system is affected in multiple neurodevelopmental disorders, (2) that the GABA A receptor heterogeneity and its well-known pharmacological properties provide a unique opportunity for targeted therapy, and (3) that interference with the GABA receptor has the potential to interfere with aspects of behavioral and even cognitive abnormalities in patients. Results of preclinical trials in several of these disorders have shown encouraging results and raised hopes for treatment in patients. Trials have been successfully conducted in human patients with Dravet syndrome and are ongoing in fragile X syndrome patients and in patients with several other types of ASD. The outcome of these trials is eagerly awaited.
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